纳武单抗免疫治疗恶性黑色素瘤后发生肠穿孔：一例报告
Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report.
作者信息
Yasuda Koji, Tanaka Toshiaki, Ishihara Soichiro, Otani Kensuke, Nishikawa Takeshi, Kiyomatsu Tomomichi, Kawai Kazushige, Hata Keisuke, Nozawa Hiroaki, Masui Yuri, Shintani Yukako, Watanabe Toshiaki
机构信息
Department of Surgical Oncology, Faculty of Medicine, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
出版信息
Surg Case Rep. 2017 Aug 25;3(1):94. doi: 10.1186/s40792-017-0370-7.
BACKGROUND
Nivolumab is a monoclonal antibody against programmed death 1 and has become a standard treatment of advanced melanoma because of its durable response and survival benefits. In this report, we present a case of severe intestinal perforation after nivolumab immunotherapy for malignant melanoma.
CASE PRESENTATION
A 73-year-old man with stage IV malignant melanoma underwent nivolumab therapy. The patient presented to our hospital because of a progressing abdominal pain. Radiological evaluation revealed evidence of free intraperitoneal air. Therefore, we diagnosed the patient as having an intestinal perforation, which was successfully resolved after surgical treatment.
CONCLUSION
Although intestinal perforation after nivolumab immunotherapy is rare, it can be severe and requires early diagnosis and emergency surgery to ensure a favorable prognosis.
背景
纳武单抗是一种抗程序性死亡蛋白1的单克隆抗体，因其持久的反应和生存益处已成为晚期黑色素瘤的标准治疗方法。在本报告中，我们介绍了一例恶性黑色素瘤患者接受纳武单抗免疫治疗后发生严重肠穿孔的病例。
病例介绍
一名73岁的IV期恶性黑色素瘤男性患者接受了纳武单抗治疗。患者因进行性腹痛前来我院就诊。影像学评估显示有腹腔内游离气体的证据。因此，我们诊断该患者为肠穿孔，手术治疗后成功治愈。
结论
尽管纳武单抗免疫治疗后肠穿孔很少见，但可能很严重，需要早期诊断和急诊手术以确保良好的预后。
Zotero 插件